反流性肾病 中国就医指南

Reflux nephropathy (RN) is a chronic kidney disorder characterized by renal scarring resulting from the abnormal retrograde flow of urine from the bladder into the ureters and kidneys—termed vesicoureteral reflux (VUR)—often compounded by recurrent or persistent urinary tract infections (UTIs). This condition is not a primary glomerular or tubulointerstitial disease but rather a structural-functional consequence of prolonged high-pressure or infected urine exposure to the renal parenchyma, leading to inflammation, fibrosis, and irreversible cortical scarring. Pathogenesis centers on two interrelated mechanisms: (1) mechanical injury from elevated intrarenal pressure during reflux episodes, particularly during voiding or bladder contraction; and (2) inflammatory damage triggered by bacterial colonization—most commonly Escherichia coli—which activates toll-like receptors, recruits neutrophils and macrophages, and promotes oxidative stress and cytokine-mediated tubulointerstitial injury. Over time, this results in focal segmental glomerulosclerosis, tubular atrophy, interstitial fibrosis, and progressive loss of nephron mass. Epidemiologically, RN is relatively rare in adults but represents a significant cause of childhood-onset chronic kidney disease (CKD); it accounts for ~10–15% of end-stage kidney disease (ESKD) cases in pediatric populations globally and up to 5% in adult CKD cohorts with unexplained hypertension or proteinuria. Prevalence peaks in early childhood, with VUR detected in ~1–2% of healthy infants and up to 30–40% of children presenting with febrile UTIs. Risk factors include congenital abnormalities of the ureterovesical junction (e.g., short intramural ureter), female sex (due to shorter urethra and higher UTI incidence), familial history of VUR or renal scarring, delayed diagnosis or inadequate management of childhood UTIs, and recurrent pyelonephritis before age 5. Socioeconomic barriers to timely pediatric urologic evaluation also contribute to disparities in outcomes. Quality of life impact is substantial and multifaceted: patients often experience fatigue, hypertension-related anxiety, dietary and fluid restrictions, sexual dysfunction, depression, and reduced work productivity. Children may face developmental delays, school absenteeism, and psychosocial stigma related to enuresis or frequent medical visits. Adults with advanced RN are at heightened risk for cardiovascular morbidity, anemia, metabolic bone disease, and premature mortality—further diminishing health-related quality of life (HRQoL) as measured by validated tools like KDQOL-SF. Early detection via renal-bladder ultrasound, dimercaptosuccinic acid (DMSA) scintigraphy, and voiding cystourethrography (VCUG) remains critical to prevent progression. While RN is irreversible once scarring occurs, optimal management focuses on halting further injury through infection control, blood pressure regulation, and renin-angiotensin system blockade.

# 反流性肾病治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：轻中度VUR（Ⅰ–Ⅲ级）、无反复尿路感染、eGFR ≥60 mL/min/1.73m²儿童及成人

• •药物治疗：抗生素预防（呋喃妥因/头孢氨苄）+ ACEI/ARB控制蛋白尿（如厄贝沙坦）

• •定期监测：泌尿系超声+DMSA扫描+尿常规+血肌酐+尿微量白蛋白

二、手术/微创介入方案

适用人群：Ⅳ–Ⅴ级VUR、反复UTI致肾瘢痕、进行性肾功能下降（eGFR <60）

• •膀胱镜下注射治疗（Deflux）：微创、日间手术

- 手术+材料费：18,000–26,000元（国产/进口凝胶）

• •开放抗反流术（Cohen/Politano-Leadbetter）：根治性强，适用于复杂解剖或失败病例

三、特殊/晚期治疗方案

适用人群：已进展至CKD 4–5期、合并高血压/贫血/代谢性酸中毒

• •多学科管理（肾内科+泌尿外科+营养科）+ RRT准备（透析通路建立）

四、方案快速选择指南

• •预算有限/儿童初发：首选保守治疗（年均≤6,000元）
• •反复感染/Ⅳ级以上：推荐Deflux微创（单次投入≤30,000元）
• •肾功能显著下降（eGFR<30）：转入CKD一体化管理，同步评估肾移植指征